Christopher Nance
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christopher Nance has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Issa Pour-Ghaz
Division of Cardiovascular Disease, University of Tennessee Health Science Center, Memphis, TN 38103, USA
2 shared publications Mark Heckle
Department of Internal Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA
2 shared publications- Rajesh Kabra
Kansas City Heart Rhythm Institute Overland Park KS USA
2 shared publications - Sharif Kayali
University of Tennessee Health Sciences Center, Department of Cardiovascular Medicine, Memphis, TN
2 shared publications - Sunil Jha
Department of Mechanical Engineering, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, India
2 shared publications Yehoshua C. Levine
Department of Internal Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA | Methodist Le Bonheur Healthcare, Memphis, TN, USA
2 shared publications
Latest Publications
- Open Access
- 10 August 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (7) , 1253-1263
A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults
Background: Parkinson's disease (PD) is a common neurodegenerative disease lacking treatments that modify progressive neuron loss. Terazosin (TZ) increases activity of the glycolytic enzyme phosphoglycerate kinase 1 and could potentially benefit impaired brain bioenergetics in PD. Preclinical data are encouraging, but we lack human data on relationships between TZ dose and measures of TZ target engagement in women and men. Objective: This study evaluated the dose-dependent effects of TZ on brain and systemic bioenergetics and safety and tolerability in neurologically healthy older adults. Methods: We administered TZ (1, 5, and 10 mg/day) to 18 neurologically healthy 60–85-year-old people. We measured plasma and cerebrospinal fluid TZ concentrations and changes in levels of whole blood ATP, brain ATP with 31 P magnetic resonance spectroscopy, cerebral metabolic activity with 18 F-FDG PET imaging, and plasma metabolomics. We also assayed tolerability and safety. Results: TZ crossed the blood-brain barrier, and 5 mg/day increased whole blood ATP and decreased brain 18 F-FDG uptake. TZ 1 mg/day lacked significant effects, and 10 mg/day did not produce additional metabolic benefit compared to 5 mg/day. These effects were similar for both sexes. Mild dizziness occurred in 3 females and 1 male. Conclusions: These findings in humans align with results from preclinical cell, animal, and epidemiological studies. Our data show that TZ increases markers of energy metabolism with a biphasic dose-response and suggest that 5 mg/day TZ may provide maximal benefit while minimizing adverse consequences of higher doses. These results lay groundwork for clinical trials in people with PD.
- 10 August 2025
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 15 (7) , 1253-1263
Open AccessA dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults
Background: Parkinson's disease (PD) is a common neurodegenerative disease lacking treatments that modify progressive neuron loss. Terazosin (TZ) increases activity of the glycolytic enzyme phosphoglycerate kinase 1 and could potentially benefit impaired brain bioenergetics in PD. Preclinical data are encouraging, but we lack human data on relationships between TZ dose and measures of TZ target engagement in women and men. Objective: This study evaluated the dose-dependent effects of TZ on brain and systemic bioenergetics and safety and tolerability in neurologically healthy older adults. Methods: We administered TZ (1, 5, and 10 mg/day) to 18 neurologically healthy 60–85-year-old people. We measured plasma and cerebrospinal fluid TZ concentrations and changes in levels of whole blood ATP, brain ATP with 31 P magnetic resonance spectroscopy, cerebral metabolic activity with 18 F-FDG PET imaging, and plasma metabolomics. We also assayed tolerability and safety. Results: TZ crossed the blood-brain barrier, and 5 mg/day increased whole blood ATP and decreased brain 18 F-FDG uptake. TZ 1 mg/day lacked significant effects, and 10 mg/day did not produce additional metabolic benefit compared to 5 mg/day. These effects were similar for both sexes. Mild dizziness occurred in 3 females and 1 male. Conclusions: These findings in humans align with results from preclinical cell, animal, and epidemiological studies. Our data show that TZ increases markers of energy metabolism with a biphasic dose-response and suggest that 5 mg/day TZ may provide maximal benefit while minimizing adverse consequences of higher doses. These results lay groundwork for clinical trials in people with PD.
- Open Access
- 1 March 2022
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 18 (2) , 1
Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy
: Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates.
- 1 March 2022
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 18 (2) , 1
Open AccessBeyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy
: Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates.
- 1 August 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (8) , S129-S130
B-PO02-083 RACIAL DIFFERENCES IN PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION
- 1 August 2021
- Published by Elsevier in Heart Rhythm
- Vol. 18 (8) , S129-S130
B-PO02-083 RACIAL DIFFERENCES IN PATIENTS UNDERGOING ATRIAL FIBRILLATION ABLATION
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
Intrathecal Methotrexate Induced Dorsal Column Syndrome (5351)
- 14 April 2020
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (15_supplem)
Intrathecal Methotrexate Induced Dorsal Column Syndrome (5351)
- 17 March 2017
- Published by Wiley in Muscle & Nerve
- Vol. 56 (1) , E4-E6
Dissociated excitation-contraction coupling in infantile Pompe disease
- 17 March 2017
- Published by Wiley in Muscle & Nerve
- Vol. 56 (1) , E4-E6
Dissociated excitation-contraction coupling in infantile Pompe disease
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Shapiro Syndrome with Agenesis of Corpus Callosum and Hyperhidrosis: A Case Report (P5.120)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Shapiro Syndrome with Agenesis of Corpus Callosum and Hyperhidrosis: A Case Report (P5.120)